Over the past 10+ years that we've been investing in healthcare innovation, we've learned that the biggest returns come from platforms that solve problems everyone feels but few can measure. NeuroTech has cracked that code. What excites us isn't just their technology—though their patented gait-plus-cognition platform is significantly more accurate than anything else on the market. It's the elegant business model: they've proven clinical validation through 100,000+ users, secured revenue with direct sales, and now they're positioned to scale exponentially through licensing to the industry's biggest players. This team knows how to build and scale. They've launched multimillion-dollar products and had multiple successful exits. They're not just scientists—they're operators who understand go-to-market strategy. But here's what sealed it for me: their beachhead in concussion management is already trusted by top-5 health systems and NFL legends. Now, with the same platform, they're expanding into a $2+ billion addressable market spanning athletic performance, aging populations, and neurofunctional health. One technology, multiple massive markets—all through low-infrastructure licensing deals. They're projecting growth from $430K to $47M in four years, with 80% of revenue from licensing by 2029. Those aren't just numbers—they're backed by partnerships already in advanced discussions with top-10 performance and leading MSK companies. We're leading this round because NeuroTech Insights represents everything we look for: proven science, defensible IP, experienced leadership, and a clear path from clinical validation to commercial scale. They're not just measuring functional health—they're building the standard for it and improving lives in the process.